BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34057003)

  • 1. Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison.
    Freeman E; Cheung W; Ferdousi S; Kavnoudias H; Majeed A; Kemp W; Roberts SK
    Scand J Gastroenterol; 2021 Aug; 56(8):942-947. PubMed ID: 34057003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre.
    Freeman E; Cheung W; Kavnoudias H; Majeed A; Kemp W; Roberts SK
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):247-253. PubMed ID: 33051707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma.
    Luerken L; Haimerl M; Doppler M; Uller W; Beyer LP; Stroszczynski C; Einspieler I
    Rofo; 2022 Oct; 194(10):1075-1086. PubMed ID: 35545102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of Radiofrequency Ablation, Microwave Ablation, and Irreversible Electroporation by Using Propensity Score Analysis for Early Stage Hepatocellular Carcinoma.
    Wada T; Sugimoto K; Sakamaki K; Takahashi H; Kakegawa T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Itoi T
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors.
    Verloh N; Jensch I; Lürken L; Haimerl M; Dollinger M; Renner P; Wiggermann P; Werner JM; Zeman F; Stroszczynski C; Beyer LP
    Radiol Oncol; 2019 Mar; 53(1):116-122. PubMed ID: 30840591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
    Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
    Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.
    Kim JG; Cho SK; Hyun D; Shin SW; Park KB; Park HS; Choo SW; Do YS; Woo SY; Baek SY
    Abdom Radiol (NY); 2021 Dec; 46(12):5735-5745. PubMed ID: 34581928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical resection versus radiofrequency ablation very early-stage HCC (≤2 cm Single HCC): A propensity score analysis.
    Chu HH; Kim JH; Kim PN; Kim SY; Lim YS; Park SH; Ko HK; Lee SG
    Liver Int; 2019 Dec; 39(12):2397-2407. PubMed ID: 31549771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation.
    He C; Wang J; Zhang Y; Cai Z; Lin X; Li S
    Cancer Med; 2020 Jul; 9(13):4699-4710. PubMed ID: 32410380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.
    Shi F; Wu M; Lian SS; Mo ZQ; Gou Q; Xu RD; Li HL; Huang ZM; Wu PH; Chen XM
    Radiology; 2019 Dec; 293(3):707-715. PubMed ID: 31638492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
    Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C
    BMC Gastroenterol; 2021 Apr; 21(1):182. PubMed ID: 33879085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.